Clinical Trial Update: Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating tipifarnib in relapsed or refractory lymphoma has completed with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Hodgkin Lymphoma
• Mantle Cell Lymphoma
• Mature T-cell and Nk-cell Non-hodgkin Lymphoma
• Nodal Marginal Zone Lymphoma
• Non-hodgkin Lymphoma
• Small Lymphocytic Lymphoma
• Splenic Marginal Zone Lymphoma
• T-cell Leukemia Lymphoma

Drugs mentioned

• Tipifarnib (tipifarnib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anaplastic Large Cell Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 2 | Status: COMPLETED | Results posted: 2011-12-07